Angiotensin II Receptor Blockade
- 1 January 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hypertension
- Vol. 41 (1) , 31-36
- https://doi.org/10.1161/01.hyp.0000047512.58862.a9
Abstract
We assessed the blockade of the renin-angiotensin system (RAS) achieved with 2 angiotensin (Ang) antagonists given either alone at different doses or with an ACE inhibitor. First, 20 normotensive subjects were randomly assigned to 100 mg OD losartan (LOS) or 80 mg OD telmisartan (TEL) for 1 week; during another week, the same doses of LOS and TEL were combined with 20 mg OD lisinopril. Then, 10 subjects were randomly assigned to 200 mg OD LOS and 160 mg OD TEL for 1 week and 100 mg BID LOS and 80 mg BID TEL during the second week. Blockade of the RAS was evaluated with the inhibition of the pressor effect of exogenous Ang I, an ex vivo receptor assay, and the changes in plasma Ang II. Trough blood pressure response to Ang I was blocked by 35±16% (mean±SD) with 100 mg OD LOS and by 36±13% with 80 mg OD TEL. When combined with lisinopril, blockade was 76±7% with LOS and 79±9% with TEL. With 200 mg OD LOS, trough blockade was 54±14%, but with 100 mg BID it increased to 77±8% ( P <0.01). Telmisartan (160 mg OD and 80 mg BID) produced a comparable effect. Thus, at their maximal recommended doses, neither LOS nor TEL blocks the RAS for 24 hours; hence, the addition of an ACE inhibitor provides an additional blockade. A 24-hour blockade can be achieved with an angiotensin antagonist alone, provided higher doses or a BID regimen is used.Keywords
This publication has 20 references indexed in Scilit:
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Pharmacologic Profile of UR-7247, an Orally Active Angiotensin II AT1 Receptor Antagonist, in Healthy VolunteersJournal of Cardiovascular Pharmacology, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Combination ACE Inhibitor and Angiotensin II Receptor Antagonist Therapy in Diabetic NephropathyAmerican Journal of Nephrology, 1999
- Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE InhibitionJournal of Cardiovascular Pharmacology, 1990
- Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinationsJournal Of Hypertension, 1990
- Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.Hypertension, 1980